Plain-English translation of NCT06877299 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lung Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining low-dose radiation, targeted radiation therapy, and a medication called tislelizumab (which helps your immune system fight cancer) along with chemotherapy can shrink lung tumors before surgery. The goal is to see if this combination approach helps more patients achieve complete cancer elimination at the time of surgery, potentially improving their chances of recovery.
Current treatments for intermediate and advanced lung cancer don't work equally well for all patients. This trial explores whether combining radiation with immune-boosting medication and chemotherapy before surgery might be more effective than standard approaches alone.
You likely qualify if…
You likely don't qualify if…
You would first receive radiation therapy over several days, followed by chemotherapy and tislelizumab given together every 3 weeks for 3 cycles (about 9 weeks total). Four to six weeks after your last medication dose, you would have surgery to remove the tumor. Throughout this time, you'll have regular imaging scans and clinic visits to monitor how well the treatment is working and to check for any side effects.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
China